Autopsy report · NCT06067802

Study of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)

“Funding was pulled”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Jerry Vockley, MD, PhD

Sponsor type

University, hospital or other

Conditions

Medium-chain Acyl-CoA Dehydrogenase Deficiency

Interventions

Triheptanoin

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer Patients
  “funding pulled” (97% match in meaning)
• Nutrition Optimization and Community Upliftment for Postpartum Recovery: Hypertension
  “Funding was cut” (78% match in meaning)
• Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
  “funding was withdrawn” (78% match in meaning)
• Clinical, Pharmacological and Molecular Effects of IV and Oral Acetaminophen in Adults With aSAH
  “Funding was stopped” (76% match in meaning)
• The Homeogenomic Trial
  “Funding withdrawn” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.